一名类风湿关节炎女性患者在对戈利木单抗发生过敏迟发反应后，成功完成阿达木单抗分级激发试验。
Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis.
作者信息
Rivolta Federica, Sangalli Andrea, Cappelletti Camilla, Chiei Gallo Alessandra, Dubini Marco, Pravettoni Valerio
机构信息
Department of Internal Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.
Allergy and Clinical Immunology Residency University of Milan Milan Italy.
出版信息
Clin Case Rep. 2023 Mar 24;11(3):e7067. doi: 10.1002/ccr3.7067. eCollection 2023 Mar.
Abstract
A graded challenge with adalimumab could be safe in case of a delayed allergic reaction to golimumab, after a detailed allergological evaluation and the exclusion of allergic sensitization using skin tests.
摘要
在进行详细的变态反应学评估并通过皮肤试验排除过敏致敏后，对于对戈利木单抗有延迟过敏反应的情况，使用阿达木单抗进行分级激发试验可能是安全的。
相似文献
1
Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis.一名类风湿关节炎女性患者在对戈利木单抗发生过敏迟发反应后，成功完成阿达木单抗分级激发试验。
Clin Case Rep. 2023 Mar 24;11(3):e7067. doi: 10.1002/ccr3.7067. eCollection 2023 Mar.
2
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.与其他皮下注射肿瘤坏死因子抑制剂相比，戈利木单抗作为类风湿关节炎二线生物制剂的两年持续用药情况：来自LORHEN注册研究的真实世界数据
Int J Rheum Dis. 2018 Feb;21(2):422-430. doi: 10.1111/1756-185X.13199. Epub 2017 Oct 30.
3
Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.体外抑制细胞因子谱可能解释类风湿关节炎中阿达木单抗治疗失败后对戈利木单抗治疗反应较差的原因。
Clin Exp Rheumatol. 2018 Jan-Feb;36(1):140-143. Epub 2017 Oct 18.
4
Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis.类风湿关节炎患者成功转换为戈利木单抗治疗与多种生物制剂相关的嗜酸性粒细胞增多和皮肤症状
Intern Med. 2017;56(12):1585-1590. doi: 10.2169/internalmedicine.56.8168. Epub 2017 Jun 15.
5
Economic impact of biologic utilization patterns in patients with psoriatic arthritis.银屑病关节炎患者生物制剂使用模式的经济影响
Clin Rheumatol. 2017 Jul;36(7):1579-1588. doi: 10.1007/s10067-017-3636-3. Epub 2017 May 4.
6
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.对停用先前抗肿瘤坏死因子治疗的活动性类风湿关节炎患者使用戈利木单抗联合甲氨蝶呤疗效的深入分析：GO-AFTER研究的事后分析
Ann Rheum Dis. 2014 Oct;73(10):1811-8. doi: 10.1136/annrheumdis-2013-203435. Epub 2013 Jul 29.
7
Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients.类风湿关节炎患者皮下注射抗肿瘤坏死因子治疗的使用及依从模式
Clin Ther. 2014 May;36(5):737-47. doi: 10.1016/j.clinthera.2014.02.019. Epub 2014 Mar 21.
8
Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.类风湿关节炎、银屑病关节炎和强直性脊柱炎二线生物制剂治疗的优化。
Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22.
9
Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.接受依那西普或阿达木单抗治疗的类风湿关节炎患者对戈利木单抗的临床反应：一项多中心活性治疗研究的结果
Curr Med Res Opin. 2017 Apr;33(4):657-666. doi: 10.1080/03007995.2016.1277195. Epub 2017 Jan 25.
10
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.英国、法国和德国生物性改善病情抗风湿药在停用依那西普后治疗类风湿关节炎的真实世界疗效
Clin Ther. 2017 Aug;39(8):1618-1627. doi: 10.1016/j.clinthera.2017.06.009. Epub 2017 Jul 17.
本文引用的文献
1
Hypersensitivity reactions to biologicals: An EAACI position paper.生物制品过敏反应：一项 EAACI 立场文件。
Allergy. 2022 Jan;77(1):39-54. doi: 10.1111/all.14984. Epub 2021 Jul 10.
2
Desensitization to biological agents used in rheumatology.对风湿病学中使用的生物制剂的脱敏作用。
Reumatologia. 2020;58(1):25-33. doi: 10.5114/reum.2020.93510. Epub 2020 Feb 28.
3
Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab.肿瘤坏死因子阻断治疗抗体 golimumab 的结构基础。
Protein Sci. 2018 Jun;27(6):1038-1046. doi: 10.1002/pro.3407. Epub 2018 Apr 17.
4
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.TNFα 拮抗剂的结构生物学：类风湿性关节炎治疗的应用。
Int J Mol Sci. 2018 Mar 7;19(3):768. doi: 10.3390/ijms19030768.
5
Cutaneous side effects of TNF-alpha inhibitors.肿瘤坏死因子-α抑制剂的皮肤副作用。
J Dtsch Dermatol Ges. 2017 Mar;15(3):281-288. doi: 10.1111/ddg.13200.
6
Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.类风湿性关节炎医疗保险患者对生物制剂过敏的风险
Arthritis Care Res (Hoboken). 2017 Oct;69(10):1526-1534. doi: 10.1002/acr.23141.
7
TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.肿瘤坏死因子（TNF）及其受体：从细胞死亡和炎症的介质到治疗的巨人——过去、现在和未来。
Cytokine Growth Factor Rev. 2014 Aug;25(4):453-72. doi: 10.1016/j.cytogfr.2014.07.016. Epub 2014 Aug 1.
8
Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.从分子角度比较阿达木单抗和英夫利昔单抗治疗肿瘤坏死因子 α 相关疾病的抑制机制。
J Biol Chem. 2013 Sep 20;288(38):27059-27067. doi: 10.1074/jbc.M113.491530. Epub 2013 Aug 13.
9
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.克罗恩病患者对英夫利昔单抗和阿达木单抗的急性和迟发性超敏反应。
J Crohns Colitis. 2012 Feb;6(1):108-11. doi: 10.1016/j.crohns.2011.08.001. Epub 2011 Aug 31.
10
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.肿瘤坏死因子拮抗剂的作用机制：全面综述
Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10.1016/j.pharmthera.2007.10.001. Epub 2007 Oct 26.
Zotero 插件